Clarus Therapeutics Holdings Inc. (NASDAQ: CRXT) Is Decrease -97.12%, So Here’s What We Can Expect On The Upswing – Marketing Sentinel
Home  »  Business   »  Clarus Therapeutics Holdings Inc. (NASDAQ: CRXT) I...

Clarus Therapeutics Holdings Inc. (NASDAQ: CRXT) Is Decrease -97.12%, So Here’s What We Can Expect On The Upswing

During the last session, Clarus Therapeutics Holdings Inc. (NASDAQ:CRXT)’s traded shares were 1.07 million. At the end of the trading day, the stock’s price was $0.29, reflecting an intraday gain of 3.35% or $0.01. The 52-week high for the CRXT share is $31.24, that puts it down -10672.41 from that peak though still a striking 10.34% gain since the share price plummeted to a 52-week low of $0.26. The company’s market capitalization is $15.66M, and the average intraday trading volume over the past 10 days was 1.47 million shares, and the average trade volume was 4.53 million shares over the past three months.

Clarus Therapeutics Holdings Inc. (CRXT) received a consensus recommendation of a Buy from analysts. That translates to a mean rating of 2.00. CRXT has a Sell rating from 0 analyst(s) out of 4 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 4 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.29.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


Clarus Therapeutics Holdings Inc. (NASDAQ:CRXT) trade information

Clarus Therapeutics Holdings Inc. (CRXT) registered a 3.35% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 3.35% in intraday trading to $0.29 this Thursday, 08/04/22, hitting a weekly high. The stock’s 5-day price performance is 4.20%, and it has moved by -28.19% in 30 days. Based on these gigs, the overall price performance for the year is -97.12%. The short interest in Clarus Therapeutics Holdings Inc. (NASDAQ:CRXT) is 2.0 million shares and it means that shorts have 0.69 day(s) to cover.

The consensus price target of analysts on Wall Street is $2.63, which implies an increase of 88.97% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $1.50 and $3.00 respectively. As a result, CRXT is trading at a discount of -934.48% off the target high and -417.24% off the low.

Clarus Therapeutics Holdings Inc. (CRXT) estimates and forecasts

Statistics show that Clarus Therapeutics Holdings Inc. has outperformed its competitors in share price, compared to the industry in which it operates. Clarus Therapeutics Holdings Inc. (CRXT) shares have gone down -78.14% during the last six months, with a year-to-date growth rate more than the industry average at 80.35% against 11.20. In the rating firms’ projections, revenue will increase 69.60% compared to the previous financial year.

Revenue for the current quarter is expected to be $5.1 million as predicted by 3 analyst(s). Meanwhile, a consensus of 3 analyst(s) estimates revenue growth to $6.56 million by the end of Sep 2022. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled $2.78 million and $4.29 million respectively. In this case, analysts expect current quarter sales to grow by 83.50% and then jump by 53.10% in the coming quarter.

While earnings are projected to return -251.70% in 2022.

CRXT Dividends

Clarus Therapeutics Holdings Inc. is due to release its next quarterly earnings on November 18. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

Clarus Therapeutics Holdings Inc. (NASDAQ:CRXT)’s Major holders

Clarus Therapeutics Holdings Inc. insiders own 2.59% of total outstanding shares while institutional holders control 23.28%, with the float percentage being 23.90%. Bracebridge Capital, LLC is the largest shareholder of the company, while 19 institutions own stock in it. As of Mar 30, 2022, the company held over 2.0 million shares (or 3.85% of all shares), a total value of $2.98 million in shares.

The next largest institutional holding, with 0.17 million shares, is of Vanguard Group, Inc. (The)’s that is approximately 0.34% of outstanding shares. At the market price on Mar 30, 2022, these shares were valued at $0.26 million.

Also, the Mutual Funds coming in first place with the largest holdings of Clarus Therapeutics Holdings Inc. (CRXT) shares are Vanguard Total Stock Market Index Fund and Bridgeway Funds Inc-Ultra Small Company Market Fund. Data provided on Mar 30, 2022 indicates that Vanguard Total Stock Market Index Fund owns about 0.17 million shares. This amounts to just over 0.32 percent of the company’s overall shares, with a $0.25 million market value. The same data shows that the other fund manager holds slightly less at 90000.0, or about 0.17% of the stock, which is worth about $0.13 million.

Leave a Comment

Your email address will not be published.

On Key

Related Posts